<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Overview of pruritus in palliative care</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Overview of pruritus in palliative care</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Overview of pruritus in palliative care</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Shalini Dalal, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Eduardo Bruera, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Thomas J Smith, MD, FACP, FASCO, FAAHPM</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jane Givens, MD, MSCE</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jul 13, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H196199662"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Pruritus (itch) is the unpleasant sensation that provokes an urge to scratch. Fortunately, pruritus is relatively uncommon in the palliative care population, and when present, may be short-lived or go unreported. However, in a minority of patients, pruritus may be severe or persistent, resulting in significant distress and poor quality of life [<a href="#rid1">1,2</a>].</p><p>The palliative care population includes a diverse group of patients with disparate advanced diseases, and the overall prevalence of significant pruritus in this population has not been well studied but may be as high as 35 percent in hospitalized palliative care patients [<a href="#rid3">3</a>].</p><p>This topic will present information on the management of common causes of pruritus in palliative care patients. Further discussion of pruritus in the general population, and in patients with uremia and cholestasis, is provided separately. (See  <a class="medical medical_review" href="/z/d/html/5576.html" rel="external">"Pruritus: Therapies for localized pruritus"</a> and  <a class="medical medical_review" href="/z/d/html/16589.html" rel="external">"Pruritus: Etiology and patient evaluation"</a> and  <a class="medical medical_review" href="/z/d/html/1985.html" rel="external">"Chronic kidney disease-associated pruritus"</a> and  <a class="medical medical_review" href="/z/d/html/3607.html" rel="external">"Pruritus associated with cholestasis"</a>.)</p><p class="headingAnchor" id="H1749534574"><span class="h2">Classification and pathophysiology</span><span class="headingEndMark"> — </span>The International Forum for the Study of Itch proposes a two-tier classification system for pruritus based on whether the etiology is known or not [<a href="#rid4">4</a>]. When the etiology is known, pruritus is further divided into dermatologic, systemic, neurologic, psychogenic, and mixed categories. (See  <a class="medical medical_review" href="/z/d/html/16589.html" rel="external">"Pruritus: Etiology and patient evaluation", section on 'Classification'</a>.)</p><p>Although the neurologic pathways that lead to itch are not fully understood, it is generally accepted that transmission of signals along unmyelinated, histamine-sensitive, and non-histamine-sensitive peripheral C nerve fibers is involved. These fibers represent a minority (up to 5 percent) of C nerve fibers in the body and are distinct from the C nerve fibers that transmit pain. They are characterized by a slow conduction velocity and extensive terminal branching. Histamine-sensitive fibers have an important role in the transmission of acute itch and itch in urticaria, while non-histamine sensitive nerve fibers have a significant role in itch transmission of most types of chronic itch, possibly accounting for the poor response of many types of chronic itch to oral antihistamines.</p><p>Both scratching and rubbing the skin inhibit the sensation of pruritus by stimulating inhibitory local circuits in the spinal cord and brain; scratching also stimulates pain receptors, which inhibits the sensation of itch. The inhibitory interneurons can be activated by both peripheral and central stimuli, and they release endogenous opiates. Additionally, central sensitization for itching may occur in patients with chronic pruritus such that noxious stimuli are perceived as itch rather than pain. (See  <a class="medical medical_review" href="/z/d/html/16589.html" rel="external">"Pruritus: Etiology and patient evaluation", section on 'Pathogenesis'</a>.)</p><p class="headingAnchor" id="H2531436888"><span class="h1">COMMON ETIOLOGIES IN PALLIATIVE CARE</span><span class="headingEndMark"> — </span>Pruritus in the palliative care population is often multifactorial, and the main causes are related to chronic kidney failure, cholestatic liver disease, hematologic or lymphoproliferative disorders, other forms of malignancy, immunotherapy in cancer patients, and drugs (especially opioids) (<a class="graphic graphic_table graphicRef114576" href="/z/d/graphic/114576.html" rel="external">table 1</a>). Additionally, dry skin is frequently present, especially in older adults, and can exacerbate all causes of pruritus.</p><p class="headingAnchor" id="H4118306178"><span class="h2">Uremic pruritus</span><span class="headingEndMark"> — </span>Pruritus is a frequent symptom in patients with advanced or end-stage kidney disease [<a href="#rid5">5</a>]. It is usually generalized and may be intermittent or continuous. Pruritus is mainly associated with chronic rather than acute kidney failure, occurring most frequently in patients who are on maintenance dialysis (40 to 50 percent of patients) [<a href="#rid6">6,7</a>]. It may accompany either primary or secondary kidney disease, such as that due to heart failure. (See  <a class="medical medical_review" href="/z/d/html/1985.html" rel="external">"Chronic kidney disease-associated pruritus", section on 'Epidemiology'</a>.)</p><p>The pathogenesis of uremic pruritus is multifactorial and includes skin atrophy and dryness due to secondary hyperparathyroidism, accumulation of pruritogenic metabolites, and abnormal mast cell proliferation in skin. Dry skin is present in 66 to 93 percent of patients with uremic pruritus. (See  <a class="medical medical_review" href="/z/d/html/1985.html" rel="external">"Chronic kidney disease-associated pruritus", section on 'Pathophysiology'</a>.)</p><p class="headingAnchor" id="H270514871"><span class="h2">Cholestasis</span><span class="headingEndMark"> — </span>The most common cholestatic liver disorders in palliative care populations are malignancy-related and are characterized by diminished delivery of bile into the intestine. Tumors that may produce extrahepatic and/or intrahepatic biliary obstruction include liver tumors (primary or metastatic), gallbladder cancers, and tumors obstructing the common bile ducts (eg, extrahepatic cholangiocarcinomas, pancreatic cancer). Approximately 45 percent of patients with malignant biliary obstruction report pruritus [<a href="#rid8">8</a>]. A presumptive diagnosis of cholestasis-associated pruritus can be made in a patient with cholestasis who complains of itching. (See  <a class="medical medical_review" href="/z/d/html/3607.html" rel="external">"Pruritus associated with cholestasis", section on 'Associated conditions'</a>.)</p><p>The pathogenesis of pruritus in cholestasis in unknown, but both peripheral and central mechanisms appear to be involved. Several hypotheses have been proposed, including bile acid accumulation, increased endogenous opioids [<a href="#rid9">9,10</a>], and elevations in lysophosphatidic acid levels. While bile acids are potential mediators of pruritus, no direct correlation has been demonstrated between pruritus and the severity of the underlying liver disease or circulating bile acid levels. (See  <a class="medical medical_review" href="/z/d/html/3607.html" rel="external">"Pruritus associated with cholestasis", section on 'Pathogenesis'</a>.)</p><p class="headingAnchor" id="H1419909218"><span class="h2">Malignancy</span><span class="headingEndMark"> — </span>Several forms of malignancy may cause pruritus, including conditions not associated with cholestasis. The most common hematologic and nonhematologic malignant disorders associated with pruritus include Hodgkin lymphoma, non-Hodgkin lymphoma, myeloproliferative syndromes such as polycythemia vera, mycosis fungoides, the leukemias, and histamine-producing gastric carcinoid tumors. (See  <a class="medical medical_review" href="/z/d/html/16589.html" rel="external">"Pruritus: Etiology and patient evaluation", section on 'Malignancy'</a>.)</p><p>Pruritus related to malignancy often represents a paraneoplastic syndrome. Less common causes include cutaneous metastases [<a href="#rid11">11</a>], lymphocytic infiltration, or the compressive effect of a tumor, such as with a tumor nerve entrapment syndrome (eg, spinal tumors causing brachioradial pruritus). (See  <a class="medical medical_review" href="/z/d/html/16589.html" rel="external">"Pruritus: Etiology and patient evaluation", section on 'Brachioradial pruritus'</a>.)</p><p>In general, the prevalence of pruritus is higher in hematologic malignancies than in solid tumors [<a href="#rid12">12</a>]. For example, several hematologic disorders, such as cutaneous T-cell lymphoma (CTCL), Hodgkin lymphoma, multiple myeloma, and leukemia, are associated with pruritus which may be caused by cutaneous disease infiltration, a paraneoplastic process, or both. Pruritus is one of the hallmarks of mycosis fungoides and its leukemic variant Sézary syndrome, with the prevalence and severity increasing in advanced stages [<a href="#rid13">13</a>]. Generalized pruritus is present in over 80 percent of patients with Sézary syndrome, approximately 50 percent with polycythemia vera, 30 percent with Hodgkin lymphoma, 10 percent with non-Hodgkin lymphoma, and 5 percent with leukemia [<a href="#rid14">14-16</a>]. With advancing disease, pruritus is often severe, diffuse, and accompanied by a burning sensation similar to neuropathic pain. (See  <a class="medical medical_review" href="/z/d/html/1674.html" rel="external">"Clinical manifestations, pathologic features, and diagnosis of mycosis fungoides", section on 'Pruritus'</a>.)</p><p>Specific syndromes include:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Paraneoplastic pruritus</strong> – The Special Interest Group of the International Forum for the Study of Itch defines paraneoplastic pruritus as "a systemic reaction to the presence of a solid tumor or a hematologic malignancy neither induced by the local presence of cancer cells nor by tumor therapy" [<a href="#rid14">14</a>]. In this setting, pruritus is usually generalized, may precede the diagnosis of the malignancy by months to years, and tends to increase in severity with advanced stages of illness [<a href="#rid17">17,18</a>].</p><p></p><p class="bulletIndent1">The pathophysiology of paraneoplastic pruritus is not well understood, but it appears to involve an immunologic reaction to tumor-specific antigens. Several data suggest that high and unbalanced production of cytokines results in histamine-independent itching. Other studies suggest a role of interleukin 31 (IL-31) as an important mediator of pruritus in CTCL [<a href="#rid19">19,20</a>]. In subjects with polycythemia vera, aquagenic pruritus has been shown to be associated with increased skin infiltration and mast cell degranulation [<a href="#rid21">21</a>], and it is more pronounced in patients showing the JAK2 617V mutation. (See  <a class="medical medical_review" href="/z/d/html/4517.html" rel="external">"Clinical manifestations and diagnosis of polycythemia vera", section on 'JAK2 mutations'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Localized pruritus</strong> – Localized pruritus at specific sites has been observed in solid tumors, such as in the scrotum (prostate cancer), perianal region (colorectal and anal cancers), vulva (cervical cancer), and nostril (brain tumors infiltrating the floor of the fourth ventricle). Cutaneous metastases, particularly breast cancer, may occasionally present with rash, pain, and/or pruritus [<a href="#rid22">22,23</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Treatment-related pruritus</strong> – Pruritus in cancer patients may also be due to cancer treatments, such as molecularly targeted therapies (eg, epidermal growth factor receptor [EGFR] inhibitors, tyrosine kinase inhibitors, BRAF inhibitors, MEK inhibitors, immune checkpoint inhibitors), and opioids, which are frequently prescribed for pain management in cancer patients (<a class="graphic graphic_table graphicRef87630" href="/z/d/graphic/87630.html" rel="external">table 2</a>). (See <a class="local">'Drug-related'</a> below.)</p><p></p><p class="headingAnchor" id="H429793638"><span class="h2">HIV/AIDS</span><span class="headingEndMark"> — </span>Pruritus is a common symptom in patients with human immunodeficiency virus (HIV) infection, with a prevalence between 31 to 45 percent. (See  <a class="medical medical_review" href="/z/d/html/16589.html" rel="external">"Pruritus: Etiology and patient evaluation", section on 'Infections'</a>.)</p><p>Pruritus due to HIV can be present with or without obvious skin lesions (eg, pruritic papular eruptions and folliculitis). In addition, drug eruptions, skin infections and infestations (eg, scabies, pediculosis corporis and pubis), and dry skin are other causes of pruritus in this patient population. HIV patients with peripheral neuropathy may also complain of localized pruritus.</p><p>A small subset of HIV patients have severe refractory pruritus, often associated with recurrent crops of discrete, erythematous, urticarial follicular papules and rare pustules with hypereosinophilia, thought to be due to hyperactivation of humoral immunity and characterized by a higher HIV viral load than in patients without this condition [<a href="#rid24">24</a>]. (See  <a class="medical medical_review" href="/z/d/html/4032.html" rel="external">"HIV-associated eosinophilic folliculitis"</a>.)</p><p class="headingAnchor" id="H3500130130"><span class="h2">Drug-related</span><span class="headingEndMark"> — </span>Opioids are likely to be a common cause of drug-related pruritus in this population. In addition, some antibiotics (such as penicillins, <a class="drug drug_general" data-topicid="9785" href="/z/d/drug information/9785.html" rel="external">trimethoprim-sulfamethoxazole</a>), statin drugs, and nonsteroidal antiinflammatory drugs have been associated with pruritus without an associated skin eruption (<a class="graphic graphic_table graphicRef87630" href="/z/d/graphic/87630.html" rel="external">table 2</a>). Some antineoplastic agents, both conventional cytotoxic drugs and molecularly targeted therapies, such as immune checkpoint inhibitors, EGFR inhibitors (including tyrosine kinase inhibitors), BRAF inhibitors, and MEK inhibitors, can also cause pruritus, even in the absence of a cutaneous abnormality. (See  <a class="medical medical_review" href="/z/d/html/16589.html" rel="external">"Pruritus: Etiology and patient evaluation", section on 'Drug reactions'</a> and  <a class="medical medical_review" href="/z/d/html/96368.html" rel="external">"Toxicities associated with immune checkpoint inhibitors", section on 'Dermatologic and mucosal toxicity'</a>.)</p><p>The mechanisms through which medications induce pruritus vary and may include drug-induced dry skin (eg, with <a class="drug drug_general" data-topicid="9209" href="/z/d/drug information/9209.html" rel="external">cetuximab</a> and other EGFR inhibitors) or phototoxicity (eg, with <a class="drug drug_general" data-topicid="9393" href="/z/d/drug information/9393.html" rel="external">doxycycline</a>). (See  <a class="medical medical_review" href="/z/d/html/2088.html" rel="external">"Cutaneous adverse events of molecularly targeted therapy and other biologic agents used for cancer therapy"</a> and  <a class="medical medical_review" href="/z/d/html/2090.html" rel="external">"Cutaneous adverse effects of conventional chemotherapy agents"</a>.)</p><p class="headingAnchor" id="H4269781350"><span class="h3">Opioids</span><span class="headingEndMark"> — </span>Opioid therapy is the cornerstone of management of moderate to severe pain in palliative care, especially in patients with cancer, and is administered through oral, transdermal, subcutaneous, neuraxial, and intravenous routes.</p><p class="headingAnchor" id="H1999226111"><span class="h4">Neuraxial opioids</span><span class="headingEndMark"> — </span>Pruritus is a frequent phenomenon with neuraxial opioids in the postoperative or postpartum settings, occurring in 30 to 100 percent of patients [<a href="#rid25">25-31</a>]. Pruritus usually begins shortly after analgesia, with the incidence, duration, and pruritic severity depending on the type and dose of the opioid and whether a local anesthetic was concomitantly administered, which decreases both the incidence and the severity of pruritus.</p><p>Intrathecal <a class="drug drug_general" data-topicid="9788" href="/z/d/drug information/9788.html" rel="external">morphine</a> administration has been associated with a high incidence of pruritus (70 to 85 percent) [<a href="#rid28">28,32,33</a>]. Lipid-soluble opioids, such as <a class="drug drug_general" data-topicid="8441" href="/z/d/drug information/8441.html" rel="external">fentanyl</a> and <a class="drug drug_general" data-topicid="9954" href="/z/d/drug information/9954.html" rel="external">sufentanil</a>, invoke pruritus of a shorter duration than intrathecal morphine. (See  <a class="medical medical_review" href="/z/d/html/4469.html" rel="external">"Adverse effects of neuraxial analgesia and anesthesia for obstetrics", section on 'Pruritus'</a>.)</p><p>However, patients receiving intrathecal opioid administration for longer duration such as for chronic pain have been shown to have the same low rate of pruritus at four weeks as those taking oral opioids [<a href="#rid34">34</a>]. Further, in the single large trial of chronic intrathecal opioids versus systemic opioids, pruritus was less common with intrathecal therapy [<a href="#rid34">34</a>].</p><p class="headingAnchor" id="H3640052531"><span class="h4">Systemic opioids</span><span class="headingEndMark"> — </span>Pruritus is about as common in patients treated with systemic opioids as in those treated with neuraxial opioids. Persistent or troublesome pruritus occurs only in approximately 1 percent of patients overall [<a href="#rid35">35,36</a>]. However, mild or transient episodes of pruritus are reported in up to 10 percent of patients on chronic systemic opioids, higher with intravenous than oral opioids. When present, pruritus is usually generalized and not associated with a rash.</p><p>Pruritus may be more common with naturally occurring opioids, such as <a class="drug drug_general" data-topicid="9291" href="/z/d/drug information/9291.html" rel="external">codeine</a> and <a class="drug drug_general" data-topicid="9788" href="/z/d/drug information/9788.html" rel="external">morphine</a>, as compared with semisynthetic (eg, <a class="drug drug_general" data-topicid="91299" href="/z/d/drug information/91299.html" rel="external">hydrocodone</a> and <a class="drug drug_general" data-topicid="9729" href="/z/d/drug information/9729.html" rel="external">oxycodone</a>) and synthetic opioids (eg, <a class="drug drug_general" data-topicid="9623" href="/z/d/drug information/9623.html" rel="external">methadone</a> and <a class="drug drug_general" data-topicid="8441" href="/z/d/drug information/8441.html" rel="external">fentanyl</a>), although data are conflicting [<a href="#rid37">37-40</a>].</p><p class="headingAnchor" id="H3840862189"><span class="h4">Mechanism</span><span class="headingEndMark"> — </span>The mechanism of opioid-induced pruritus (OIP) is uncertain [<a href="#rid41">41</a>]. Many mechanisms have been postulated that involve peripheral-acting (including histamine release from mast cells) and/or central-acting pathways, but no single mechanism can explain all instances of OIP:</p><p class="bulletIndent1"><span class="glyph">●</span>OIP may be mediated through central mu-opioid receptors [<a href="#rid42">42-51</a>]. A central role for mu-opioid receptors is supported by the fact that mu-opioid receptor antagonists have a primary role in preventing or treating OIP caused by neuraxial opioid administration, at least in the perioperative setting. (See <a class="local">'Opioid-induced pruritus'</a> below and  <a class="medical medical_review" href="/z/d/html/4469.html" rel="external">"Adverse effects of neuraxial analgesia and anesthesia for obstetrics", section on 'Pruritus'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>OIP arising from central mechanisms may also be mediated through 5 hydroxytryptamine subtype 3 (5-HT3) receptors and may be potentially improved through the use of 5-HT3 antagonists such as <a class="drug drug_general" data-topicid="9719" href="/z/d/drug information/9719.html" rel="external">ondansetron</a> [<a href="#rid52">52-55</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>On the other hand, both peripheral and central mechanisms appear to play a role in pruritus associated with systemically administered opioids:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Opioid peripheral effects can include cutaneous vascular (wheal and flare) responses, which, depending on the opioid, involve histamine release from mast cells, a direct opioid receptor effect on the vasculature, or both [<a href="#rid49">49,56,57</a>]. Opioids such as <a class="drug drug_general" data-topicid="9788" href="/z/d/drug information/9788.html" rel="external">morphine</a>, <a class="drug drug_general" data-topicid="9608" href="/z/d/drug information/9608.html" rel="external">meperidine</a>, and <a class="drug drug_general" data-topicid="8441" href="/z/d/drug information/8441.html" rel="external">fentanyl</a> invoke both pruritus and vascular responses; while <a class="drug drug_general" data-topicid="9678" href="/z/d/drug information/9678.html" rel="external">naloxone</a>, a mu-opioid receptor antagonist, completely blocked fentanyl effects, it did so only partially for morphine and meperidine [<a href="#rid56">56</a>]. Further, while antihistamines had no effect on fentanyl cutaneous reaction, they exhibited partial blocking effects for the cutaneous vascular response with morphine and meperidine.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In other experiments, <a class="drug drug_general" data-topicid="9788" href="/z/d/drug information/9788.html" rel="external">morphine</a> and <a class="drug drug_general" data-topicid="9291" href="/z/d/drug information/9291.html" rel="external">codeine</a> (but not <a class="drug drug_general" data-topicid="8441" href="/z/d/drug information/8441.html" rel="external">fentanyl</a>, <a class="drug drug_general" data-topicid="9733" href="/z/d/drug information/9733.html" rel="external">oxymorphone</a>, or <a class="drug drug_general" data-topicid="10010" href="/z/d/drug information/10010.html" rel="external">tramadol</a>) have been shown to directly release histamine from skin mast cells in a nonimmunologic manner [<a href="#rid49">49,50,56,58-60</a>].</p><p></p><p class="bulletIndent1">These data suggest that effects of <a class="drug drug_general" data-topicid="8441" href="/z/d/drug information/8441.html" rel="external">fentanyl</a>, <a class="drug drug_general" data-topicid="9733" href="/z/d/drug information/9733.html" rel="external">oxymorphone</a>, and <a class="drug drug_general" data-topicid="10010" href="/z/d/drug information/10010.html" rel="external">tramadol</a> on pruritus with or without wheal and flare response are histamine independent and involve mu-opioid receptors, while the effect of other opioids, such as <a class="drug drug_general" data-topicid="9788" href="/z/d/drug information/9788.html" rel="external">morphine</a>, <a class="drug drug_general" data-topicid="9291" href="/z/d/drug information/9291.html" rel="external">codeine</a>, and <a class="drug drug_general" data-topicid="9608" href="/z/d/drug information/9608.html" rel="external">meperidine</a>, involve both mu-opioid receptor and histamine-related mechanisms [<a href="#rid49">49,56,57</a>]. Although more research is warranted, studies suggest that attempts to antagonize the pruritic or cutaneous vascular effects of systemically administered opioids that are known to release histamine with antihistamines alone will only have partial effects. (See <a class="local">'Systemic drugs for patients with persistent or generalized pruritus'</a> below.)</p><p></p><p>Management of OIP is discussed below. (See <a class="local">'Opioid-induced pruritus'</a> below.)</p><p class="headingAnchor" id="H1627427591"><span class="h1">MANAGEMENT</span><span class="headingEndMark"> — </span>Due to the different causes and underlying mechanisms of pruritus in palliative care patients, there is no universally effective antipruritic strategy. An individualized stepwise approach that incorporates symptom severity, clinical circumstances and goals of care, the presumed etiology of the pruritus, and response to initial therapies is recommended.</p><p>Our approach is to begin with general skin care and topical therapies, due to the lower propensity of side effects, especially when pruritus is intermittent, mild, and/or localized. (See <a class="local">'Skin care measures for all patients'</a> below and <a class="local">'Topical therapies'</a> below.)</p><p>For patients with persistent or generalized pruritus, or those in whom topical therapies are not effective, we use systemic pharmacologic agents. (See <a class="local">'Systemic drugs for patients with persistent or generalized pruritus'</a> below.)</p><p>When known, the presumptive etiology can guide the choice of initial therapy. (See <a class="local">'Recommendations for specific clinical syndromes'</a> below.)</p><p class="headingAnchor" id="H639465234"><span class="h2">Skin care measures for all patients</span><span class="headingEndMark"> — </span>General skin care measures are recommended for all patients, regardless of the cause of pruritus. Dry skin can accompany and exacerbate all causes of pruritus; therefore, measures to regularly lubricate the skin with nonfragrant topical emollients, especially after bathing, are important. Patients should be educated on wearing nonirritating and loose clothing, avoiding skin irritants such as perfumes, and maintaining a cool, humidified environment. (See  <a class="medical medical_review" href="/z/d/html/131632.html" rel="external">"Pruritus: Therapies for generalized pruritus", section on 'Elimination of aggravating factors'</a>.)</p><p class="headingAnchor" id="H2850434735"><span class="h2">Topical therapies</span></p><p class="headingAnchor" id="H2314520070"><span class="h3">Treatments for most patients</span><span class="headingEndMark"> — </span>A number of topical agents, such as cooling agents, anesthetics, substance P and calcineurin inhibitors, corticosteroids, and antihistamines have been used for symptomatic improvement of itch, with varying degrees of success. There are no comparative data, and one class of topical therapy cannot be recommended over any other for specific patients. These treatments are described briefly below and are discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/5576.html" rel="external">"Pruritus: Therapies for localized pruritus", section on 'Topical therapies'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>For localized areas of itching with no evidence of inflammation, the initial approach in the palliative care population includes the use of topical cooling agents (either 1% menthol or 0.5 to 2% <a class="drug drug_general" data-topicid="104178" href="/z/d/drug information/104178.html" rel="external">camphor</a>), which substitute the sensation of a cooling effect for itching and are well tolerated. They can be used with or without topical anesthetics.</p><p></p><p class="bulletIndent1">Available topical anesthetic agents include <a class="drug drug_general" data-topicid="9558" href="/z/d/drug information/9558.html" rel="external">lidocaine</a>, <a class="drug drug_general" data-topicid="10228" href="/z/d/drug information/10228.html" rel="external">prilocaine</a> and <a class="drug drug_general" data-topicid="10226" href="/z/d/drug information/10226.html" rel="external">pramoxine</a>. Examples of common over-the-counter preparations include lidocaine cream (2.5%), lidocaine patch (5%), <a class="drug drug_general" data-topicid="114508" href="/z/d/drug information/114508.html" rel="external">lidocaine-menthol</a> cream, lidocaine-menthol patch, mixture of lidocaine 2.5% and prilocaine 2.5% cream (EMLA), and pramoxine 1% lotion. Application of large quantities of lidocaine or EMLA should be avoided because systemic absorption may occur. Methemoglobinemia is a potential consequence of EMLA use in young children. (See  <a class="medical medical_review" href="/z/d/html/6338.html" rel="external">"Clinical use of topical anesthetics in children"</a> and  <a class="medical medical_review" href="/z/d/html/5576.html" rel="external">"Pruritus: Therapies for localized pruritus", section on 'Topical anesthetics'</a>.)</p><p></p><p class="bulletIndent1"><a class="drug drug_general" data-topicid="10226" href="/z/d/drug information/10226.html" rel="external">Pramoxine</a> 1% lotion, applied twice a day to the affected area, was shown to be superior to placebo in reduction of pruritus symptoms (61 versus 12 percent) in a four-week randomized trial of 28 patients with uremic pruritus [<a href="#rid61">61</a>]. (See <a class="local">'Uremia'</a> below.)</p><p></p><p class="headingAnchor" id="H3913790716"><span class="h3">Patients with inflammation</span></p><p class="bulletIndent1"><span class="glyph">●</span>Topical corticosteroids are effective for treatment of inflammatory skin disease, which often results in the concomitant relief of the associated pruritus. These agents are <strong>not</strong> indicated for pruritus without evidence of skin inflammation. (See  <a class="medical medical_review" href="/z/d/html/5576.html" rel="external">"Pruritus: Therapies for localized pruritus", section on 'Topical anti-inflammatory agents'</a>.)</p><p></p><p class="headingAnchor" id="H1613554232"><span class="h3">Other topical treatments</span></p><p class="bulletIndent1"><span class="glyph">●</span>Topical antihistamines are generally avoided in this patient population due to concern for systemic absorption. <a class="drug drug_general" data-topicid="9390" href="/z/d/drug information/9390.html" rel="external">Doxepin</a> (5%) cream has been used for atopic dermatitis, but there are insufficient data for use of other antihistamines, including topical <a class="drug drug_general" data-topicid="9369" href="/z/d/drug information/9369.html" rel="external">diphenhydramine</a>. Topical diphenhydramine toxicity has been well described due in part to its erratic absorption [<a href="#rid62">62</a>]. Potential adverse effects of topical doxepin include drowsiness and dry mouth from systemic absorption, as well as contact dermatitis and stinging or burning at the site of application. Its use should therefore be limited to very localized areas of pruritus involving less than 10 percent of the body surface, and to no more than a few days, with a maximum topical dose of 3 g per application up to three times daily. (See  <a class="medical medical_review" href="/z/d/html/5576.html" rel="external">"Pruritus: Therapies for localized pruritus", section on 'Topical antihistamines'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The role of other topical therapies such as <a class="drug drug_general" data-topicid="8840" href="/z/d/drug information/8840.html" rel="external">capsaicin</a> (8-methyl-N-vanillyl-6 nonenamide) and calcineurin inhibitors is unclear. Capsaicin is a substance derived from chili peppers that has been used for the treatment of chronic pain and pruritus [<a href="#rid63">63</a>]. It acts by activating the transient receptor potential vanilloid 1 (TRPV1) ion channel on C fibers, which stimulates neurons to release substance P, eventually depleting it. Initial application of capsaicin (0.025 to 0.1%) ointment causes a burning sensation that may last for up to 30 minutes, which limits its use for localized pruritus and contributes to poor compliance. A topical anaesthetic applied prior to capsaicin may help. A systematic review of randomized trials found insufficient evidence for efficacy in patients with pruritus [<a href="#rid64">64</a>]. (See  <a class="medical medical_review" href="/z/d/html/5576.html" rel="external">"Pruritus: Therapies for localized pruritus", section on 'Topical capsaicin'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Topical calcineurin inhibitors, including <a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">tacrolimus</a> (0.03 and 0.1% ointments) and <a class="drug drug_general" data-topicid="10162" href="/z/d/drug information/10162.html" rel="external">pimecrolimus</a> (1% cream), may be useful for itch associated with various inflammatory skin disorders, such as atopic dermatitis, anogenital pruritus, chronic hand dermatitis, and nonsclerotic chronic graft-versus-host disease. As with <a class="drug drug_general" data-topicid="8840" href="/z/d/drug information/8840.html" rel="external">capsaicin</a>, the mechanism of action may also involve initial release of substance P, and they may also be associated with an initial burning sensation. (See  <a class="medical medical_review" href="/z/d/html/5576.html" rel="external">"Pruritus: Therapies for localized pruritus", section on 'Topical anti-inflammatory agents'</a> and  <a class="medical medical_review" href="/z/d/html/13760.html" rel="external">"Cutaneous manifestations of graft-versus-host disease (GVHD)", section on 'Overview'</a>.)</p><p></p><p class="headingAnchor" id="H3236560564"><span class="h2">Systemic drugs for patients with persistent or generalized pruritus</span><span class="headingEndMark"> — </span>Several pharmacologic therapies are used in palliative care patients with pruritus. Antihistamines (H1 receptor antagonists) are not routinely recommended, as most of the causes of pruritus in palliative care do not involve histamine release. However, the sedating effect of antihistamines might have a beneficial effect in patients who are unable to sleep due to pruritus symptoms.</p><p>If effective, all systemic drugs tend to work quickly. For most patients with pruritus, we would usually start with one drug class and, if there is no relief within a day, we would move on to a different class. Specific treatments for conditions common in palliative care patients are presented below. (See <a class="local">'Recommendations for specific clinical syndromes'</a> below.)</p><p class="headingAnchor" id="H2722239527"><span class="h3">Efficacy in palliative care patients</span><span class="headingEndMark"> — </span>Data to support efficacy of these agents in the general patient population are reviewed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/131632.html" rel="external">"Pruritus: Therapies for generalized pruritus"</a>.)</p><p>In a 2023 review of 91 studies assessing the effects of 51 different interventions for pruritus of multiple origins in participants with advanced disease, the strongest evidence of benefit was for gamma-aminobutyric acid (GABA) analogues compared with placebo in patients with uremic pruritus (five trials), and lesser benefit from treatment with kappa-opioid receptor agonists compared with placebo (six trials) [<a href="#rid65">65</a>]. In addition, seven studies compared <a class="drug drug_general" data-topicid="8483" href="/z/d/drug information/8483.html" rel="external">gabapentin</a> with antihistamines, showing superiority of gabapentin in most cases. Evidence was uncertain or low regarding treatments for cholestatic pruritus, and no therapies for pruritus associated with malignancy were found to be effective.</p><p class="headingAnchor" id="H3039236293"><span class="h2">Recommendations for specific clinical syndromes</span></p><p class="headingAnchor" id="H3206508498"><span class="h3">Cholestasis</span><span class="headingEndMark"> — </span>For patients with malignant extrahepatic biliary obstruction, bile duct stenting should be considered if the clinical situation is appropriate and consistent with the goals of care. The most common initial pharmacologic therapies include bile acid sequestrants, rifampicin, and opioid antagonists. These and other pharmacologic treatments for pruritus due to cholestasis are discussed in detail elsewhere. (See  <a class="medical medical_review" href="/z/d/html/3607.html" rel="external">"Pruritus associated with cholestasis", section on 'Management'</a>.)</p><p class="headingAnchor" id="H285079361"><span class="h3">Uremia</span><span class="headingEndMark"> — </span>All patients with pruritus due to uremia should be treated with emollients and other topical analgesics. For treatment of uremic pruritus that is refractory to optimized dialysis, topical treatments, and general skin care measures, we use oral <a class="drug drug_general" data-topicid="8483" href="/z/d/drug information/8483.html" rel="external">gabapentin</a>. Further discussion is provided elsewhere. (See  <a class="medical medical_review" href="/z/d/html/1919.html" rel="external">"Kidney palliative care: Principles, benefits, and core components", section on 'Pruritus'</a>.)</p><p class="headingAnchor" id="H2883433053"><span class="h3">Hematologic diseases, tumor infiltration, paraneoplastic pruritus</span><span class="headingEndMark"> — </span>A number of drugs, such as H1 antihistamines, corticosteroids, antidepressants, gabapentinoids, opioid antagonists, and neurokinin 1 (NK1) receptor antagonists have been used to control pruritus in this patient population, as reported in small uncontrolled studies or case reports. There are no comparative trials, and the choice of initial therapy is empiric. As in other conditions associated with pruritus, H1 antihistamines are usually ineffective in paraneoplastic pruritus, but they have beneficial sedating effects when nocturnal itching is present. Examples include <a class="drug drug_general" data-topicid="8544" href="/z/d/drug information/8544.html" rel="external">hydroxyzine</a> at doses of 10 to 25 mg at night.</p><p class="bulletIndent1"><span class="glyph">●</span>Selective serotonin reuptake inhibitors or gabapentinoid drugs are usually considered first, and may be used on combination if needed. Moderate and usually rapid-onset (within days) antipruritic effects have been suggested in some studies with <a class="drug drug_general" data-topicid="9743" href="/z/d/drug information/9743.html" rel="external">paroxetine</a> (5 to 20 mg/day), <a class="drug drug_general" data-topicid="9886" href="/z/d/drug information/9886.html" rel="external">sertraline</a> (25 to 50 mg) and <a class="drug drug_general" data-topicid="8474" href="/z/d/drug information/8474.html" rel="external">fluvoxamine</a> (25 to 100 mg/day) [<a href="#rid66">66,67</a>]. In several case reports, <a class="drug drug_general" data-topicid="9656" href="/z/d/drug information/9656.html" rel="external">mirtazapine</a> (15 to 30 mg/day) has also demonstrated antipruritic effects [<a href="#rid11">11,68-70</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The gabapentinoids <a class="drug drug_general" data-topicid="8483" href="/z/d/drug information/8483.html" rel="external">gabapentin</a> (300 mg, up to 3600 mg maximum daily divided in up to three doses) and <a class="drug drug_general" data-topicid="9473" href="/z/d/drug information/9473.html" rel="external">pregabalin</a> (75 mg, up to 600 mg/day divided in up to three doses) may also be effective as antipruritic therapies [<a href="#rid71">71-73</a>]. The mechanism of action is likely a combination of central inhibition of pruritus perception, decreased excitability of spinal and supraspinal neurons, and inhibition of serotonergic circuits. Gabapentin in combination with <a class="drug drug_general" data-topicid="9656" href="/z/d/drug information/9656.html" rel="external">mirtazapine</a> was found to be helpful in relieving pruritus in patients with CTCL [<a href="#rid70">70</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Glucocorticoids, such as <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a> (30 to 40 mg) tapered off over three weeks has been reported to be helpful in treating pruritus in lymphoma patients not responsive to above therapies. Steroids have been shown to reduce IL-31 expression in malignant T cells, which is correlated with reduced itch in CTCL patients [<a href="#rid20">20</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Other agents to consider in patients with refractory pruritus include <a class="drug drug_general" data-topicid="10095" href="/z/d/drug information/10095.html" rel="external">thalidomide</a>, <a class="drug drug_general" data-topicid="9679" href="/z/d/drug information/9679.html" rel="external">naltrexone</a>, <a class="drug drug_general" data-topicid="9179" href="/z/d/drug information/9179.html" rel="external">butorphanol</a>, and <a class="drug drug_general" data-topicid="9305" href="/z/d/drug information/9305.html" rel="external">aprepitant</a>. Thalidomide (50 to 100 mg), an immunomodulatory agent, has been shown in case reports to improve refractory pruritus in patients with mycosis fungoides and Hodgkin lymphoma [<a href="#rid74">74,75</a>]. Although the exact mechanism by which thalidomide exhibits its antipruritic effects is not understood, immunomodulatory effects result in destruction of lymphoma cells or a decrease in the production of pruritogenic mediators [<a href="#rid76">76</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In case reports, the opioid receptor antagonist <a class="drug drug_general" data-topicid="9679" href="/z/d/drug information/9679.html" rel="external">naltrexone</a> (25 to 100 mg/day orally) was shown to mitigate pruritus symptoms in patients with aquagenic pruritus, non-Hodgkin lymphoma, and mycosis fungoides [<a href="#rid77">77-79</a>]. <a class="drug drug_general" data-topicid="9179" href="/z/d/drug information/9179.html" rel="external">Butorphanol</a> is a kappa-opioid agonist and mu-opioid antagonist that has demonstrated antipruritic effects in one patient with non-Hodgkin lymphoma when given intranasally at dose of 1 mg/day [<a href="#rid80">80,81</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9305" href="/z/d/drug information/9305.html" rel="external">Aprepitant</a> is a NK1 receptor antagonist that is approved for prevention and treatment of chemotherapy-induced nausea and vomiting. In case reports, aprepitant given orally once daily (dose of 80 mg) or for three consecutive days every two weeks (125 mg on day 1 and 80 mg on days 2 and 3) provided benefit for relief of pruritus [<a href="#rid82">82,83</a>]. However the cost, may be prohibitive.</p><p></p><p class="headingAnchor" id="H2050021101"><span class="h3">Opioid-induced pruritus</span><span class="headingEndMark"> — </span>Treatment of opioid-induced pruritus (OIP), especially pruritus related to spinal administration of opioids, remains a challenge. Due to the prevalence of pruritus with neuraxial opioids administered in the perioperative setting, prevention is the key, using the lowest effective doses of opioids and prophylactic antipruritic therapy starting simultaneously with the neuraxial opioid. The options for prophylactic treatment include small doses of opioid antagonists, 5 hydroxytryptamine subtype 3 (5-HT3) receptor antagonists, <a class="drug drug_general" data-topicid="9826" href="/z/d/drug information/9826.html" rel="external">propofol</a>, anticonvulsants, and glucocorticoids. This subject is discussed in detail elsewhere. (See  <a class="medical medical_review" href="/z/d/html/4469.html" rel="external">"Adverse effects of neuraxial analgesia and anesthesia for obstetrics", section on 'Pruritus'</a>.)</p><p>First-line treatment options for symptomatic pruritus from a systemically administered opioid include rotation to a different opioid and antipruritic therapies. For patients with pruritus related to oral or intravenous <a class="drug drug_general" data-topicid="9788" href="/z/d/drug information/9788.html" rel="external">morphine</a>, a trial of an oral antihistamine is reasonable, such as <a class="drug drug_general" data-topicid="8544" href="/z/d/drug information/8544.html" rel="external">hydroxyzine</a> 10 to 25 mg two to three times daily, monitoring for excessive sedation; another option is rotation to a different opioid with negligible to absent histamine-releasing properties (eg, <a class="drug drug_general" data-topicid="8441" href="/z/d/drug information/8441.html" rel="external">fentanyl</a>, <a class="drug drug_general" data-topicid="9733" href="/z/d/drug information/9733.html" rel="external">oxymorphone</a>, or <a class="drug drug_general" data-topicid="9729" href="/z/d/drug information/9729.html" rel="external">oxycodone</a>). (See <a class="local">'Mechanism'</a> above.)</p><p>For pruritus related to <a class="drug drug_general" data-topicid="8441" href="/z/d/drug information/8441.html" rel="external">fentanyl</a> or <a class="drug drug_general" data-topicid="9733" href="/z/d/drug information/9733.html" rel="external">oxymorphone</a>, depending on the severity of symptoms, pharmacologic treatment or opioid rotation may be considered. Nonpharmacologic treatments, such as cool compresses or moisturizers, may be beneficial for certain patients.</p><p>For most patients receiving systemic opioids, prophylactic antipruritic agents are not recommended. However, use of an opioid antagonist or a mixed opioid receptor agonist/antagonist may be considered in select cases, such as with use of epidural or intrathecal opioids:</p><p class="bulletIndent1"><span class="glyph">●</span>Opioid antagonists such as <a class="drug drug_general" data-topicid="9678" href="/z/d/drug information/9678.html" rel="external">naloxone</a> and <a class="drug drug_general" data-topicid="9679" href="/z/d/drug information/9679.html" rel="external">naltrexone</a> may be useful [<a href="#rid84">84</a>], but they can be associated with reversal of analgesic effects at higher doses. For naloxone, studies suggest that the most useful dose range is 0.25 to 1 mcg/kg. As naloxone has a short half-life of approximately one hour, continuous intravenous infusion is necessary. Doses should not exceed 2 mcg/kg/hour due to the risk of reversal of analgesic effects. Naltrexone, an analogue of naloxone, has a longer half-life of four to five hours and has the advantage of being available in an oral formulation. For OIP prophylaxis, doses of 6 and 9 mg given once or twice daily have been shown to be effective but may decrease analgesic efficacy in a dose-dependent manner [<a href="#rid85">85,86</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9676" href="/z/d/drug information/9676.html" rel="external">Nalbuphine</a>, a mixed opioid receptor agonist/antagonist, may be more useful than the pure opioid antagonists as it is not associated with reversal of analgesic effects. It can be administered spinally and via subcutaneous or intravenous routes. In a systematic review of 10 randomized controlled trials [<a href="#rid87">87</a>], low-dose nalbuphine treatment (2.5 or 5 mg intravenously) provided greater efficacy in treating OIP compared with placebo or other agents, such as <a class="drug drug_general" data-topicid="9369" href="/z/d/drug information/9369.html" rel="external">diphenhydramine</a>, <a class="drug drug_general" data-topicid="9678" href="/z/d/drug information/9678.html" rel="external">naloxone</a>, and <a class="drug drug_general" data-topicid="9826" href="/z/d/drug information/9826.html" rel="external">propofol</a>, without affecting analgesia or sedation. Although most of the studies were in patients undergoing neuraxial analgesia, 3 of the 10 trials included patients receiving intravenous patient-controlled analgesia.</p><p></p><p class="headingAnchor" id="H2796095492"><span class="h3">Pruritus of unknown cause</span><span class="headingEndMark"> — </span>For patients with pruritus of unknown cause who have not responded to topical therapy, reasonable options for first-line therapy serotonin-modulating drugs such as <a class="drug drug_general" data-topicid="9656" href="/z/d/drug information/9656.html" rel="external">mirtazapine</a>, <a class="drug drug_general" data-topicid="9886" href="/z/d/drug information/9886.html" rel="external">sertraline</a>, or <a class="drug drug_general" data-topicid="9743" href="/z/d/drug information/9743.html" rel="external">paroxetine</a> [<a href="#rid88">88</a>]. Patients with concomitant sleep or appetite issues (common in palliative care patients) may benefit with mirtazapine 7.5 to 30 mg at bedtime. At these doses, mirtazapine has also been found useful in pruritus due to malignancy, cholestasis, and uremia. Sertraline at 25 to 100 mg or paroxetine at 5 to 20 mg are other alternatives that can be considered first or if there is no relief with mirtazapine, and they have also been found useful in pruritus associated with cholestasis, uremia, or opioids. While 5‑HT3 receptor antagonists such as <a class="drug drug_general" data-topicid="9719" href="/z/d/drug information/9719.html" rel="external">ondansetron</a> have been shown to be useful in other pruritus conditions (opioids, uremia, and cholestasis) we do not recommend use as first-line therapy due to the expense and adverse effects of headaches and constipation. <a class="drug drug_general" data-topicid="8483" href="/z/d/drug information/8483.html" rel="external">Gabapentin</a> usually starting at 300 mg at bedtime may be considered alone as first-line therapy or in addition to the selective serotonin reuptake inhibitors.</p><p>Glucocorticoids such as <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a> 30 mg/day or <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">dexamethasone</a> 4 to 8 mg/day may be considered if pruritus is acute, severe, and remains refractory. If effective, these drugs tend to work quickly and ideally should be tapered off within two to three weeks. Longer duration may be associated with undesired side effects including hyperglycemia, gastric ulcers, and adrenocorticotropic hormone (ACTH) suppression. If discontinuation is not possible, the lowest effective dose should be continued with added gastrointestinal protection.</p><p class="headingAnchor" id="H616648268"><span class="h2">Phototherapy</span><span class="headingEndMark"> — </span>For refractory cases, phototherapy using ultraviolet B light has been shown to be most useful in pruritus associated with uremia [<a href="#rid89">89</a>], but it may also benefit pruritus associated with cholestasis and malignant skin infiltrations. (See  <a class="medical medical_review" href="/z/d/html/131632.html" rel="external">"Pruritus: Therapies for generalized pruritus", section on 'Other therapies'</a> and  <a class="medical medical_review" href="/z/d/html/131632.html" rel="external">"Pruritus: Therapies for generalized pruritus", section on 'Phototherapy'</a>.)</p><p class="headingAnchor" id="H2784370914"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/119531.html" rel="external">"Society guideline links: Palliative care"</a>.)</p><p class="headingAnchor" id="H1222561666"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span>The main causes of pruritus in the palliative care population are chronic renal failure, liver disease, hematologic or lymphoproliferative disorders, malignancy, and drugs (especially opioids) (<a class="graphic graphic_table graphicRef114576" href="/z/d/graphic/114576.html" rel="external">table 1</a>). Xerosis (dry skin) is frequently present in older adults and can accompany or exacerbate all causes of pruritus. (See <a class="local">'Common etiologies in palliative care'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Treatment involves an individualized stepwise approach that depends upon the severity of symptoms, the patient's clinical circumstances and goals of care, and the response to initial therapies. Although systematic evaluation and treatment directed at eradicating the primary cause of the pruritus may be recommended (eg, stenting for biliary obstruction), this is not a feasible option for the vast majority of palliative care patients, and therapy is directed at reducing itch regardless of etiology. (See <a class="local">'Management'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>General skin care measures are recommended for all patients, regardless of the cause of the pruritus. Dry skin can exacerbate all causes of pruritus; therefore, measures to regularly lubricate the skin with nonfragrant topical emollients, especially after bathing, are important. (See <a class="local">'Skin care measures for all patients'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Topical therapies are generally preferred as initial treatment due to a lower propensity for side effects, especially when pruritus is mild, intermittent, or localized. Systemic drugs may be recommended for persistent and/or generalized pruritus, or when topical therapies are not effective for localized pruritus. If therapy is initiated, ongoing evaluation of the benefit versus the burden and side effects of the ongoing treatment is needed. (See <a class="local">'Topical therapies'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Histamine release does not play a meaningful role in the pruritus typically observed in palliative patients; therefore, oral antihistamines are not usually beneficial. (See <a class="local">'Systemic drugs for patients with persistent or generalized pruritus'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For patients with malignant extrahepatic biliary obstruction, bile duct stenting is reasonable in the setting of biliary obstruction if it is consistent with the goals of care. Further treatments are discussed elsewhere. (See <a class="local">'Cholestasis'</a> above and  <a class="medical medical_review" href="/z/d/html/3607.html" rel="external">"Pruritus associated with cholestasis", section on 'Management'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For treatment of uremic pruritus that is refractory to optimized dialysis, topical treatments and general skin care measures, we use oral <a class="drug drug_general" data-topicid="8483" href="/z/d/drug information/8483.html" rel="external">gabapentin</a>. This and other treatments are discussed in detail elsewhere. (See <a class="local">'Uremia'</a> above and  <a class="medical medical_review" href="/z/d/html/1919.html" rel="external">"Kidney palliative care: Principles, benefits, and core components", section on 'Pruritus'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Treatment of opioid-induced pruritus (OIP) is challenging. Due to the high prevalence of pruritus with neuraxial opioids, simultaneous prophylactic therapy is a reasonable approach for most patients. For patients with OIP who are receiving systemic opioids, oral antihistamines (for patients receiving systemic <a class="drug drug_general" data-topicid="9788" href="/z/d/drug information/9788.html" rel="external">morphine</a>) and switching to an alternative opioid are the preferred approaches. (See <a class="local">'Opioid-induced pruritus'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For patients with malignant skin infiltrations, hematologic diseases associated with pruritus, and paraneoplastic pruritus, a number of diverse groups of drugs, such as H1 antihistamines, corticosteroids, antidepressants, anticonvulsants, opioid antagonists, and neurokinin 1 (NK1) receptor antagonists, have been used to control pruritus. There are no comparative trials, and the choice of initial therapy is empiric. (See <a class="local">'Hematologic diseases, tumor infiltration, paraneoplastic pruritus'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>If effective, all systemic drugs tend to work quickly. For most patients with pruritus, we would usually start with one drug class, and if there is no relief within a day, we would move on to a different class.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For refractory cases, phototherapy using ultraviolet B light is most useful in pruritus associated with uremia, but it may also benefit pruritus associated with cholestasis and malignant skin infiltrations. The treatment sessions are usually three times per week, and this may not be practical in terminally ill patients, depending on the clinical circumstances and goals of care. (See <a class="local">'Phototherapy'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Erturk IE, Arican O, Omurlu IK, Sut N. Effect of the pruritus on the quality of life: a preliminary study. Ann Dermatol 2012; 24:406.</a></li><li><a class="nounderline abstract_t">Desai NS, Poindexter GB, Monthrope YM, et al. A pilot quality-of-life instrument for pruritus. J Am Acad Dermatol 2008; 59:234.</a></li><li><a class="nounderline abstract_t">Neloska L, Damevska K, Kuzmanova A, et al. Dermatological diseases in palliative care patients: a prospective study of 271 patients. J Dtsch Dermatol Ges 2017; 15:621.</a></li><li><a class="nounderline abstract_t">Ständer S, Weisshaar E, Mettang T, et al. Clinical classification of itch: a position paper of the International Forum for the Study of Itch. Acta Derm Venereol 2007; 87:291.</a></li><li><a class="nounderline abstract_t">Suseł J, Batycka-Baran A, Reich A, Szepietowski JC. Uraemic pruritus markedly affects the quality of life and depressive symptoms in haemodialysis patients with end-stage renal disease. Acta Derm Venereol 2014; 94:276.</a></li><li><a class="nounderline abstract_t">Pisoni RL, Wikström B, Elder SJ, et al. Pruritus in haemodialysis patients: International results from the Dialysis Outcomes and Practice Patterns Study (DOPPS). Nephrol Dial Transplant 2006; 21:3495.</a></li><li><a class="nounderline abstract_t">Mettang T, Pauli-Magnus C, Alscher DM. Uraemic pruritus--new perspectives and insights from recent trials. Nephrol Dial Transplant 2002; 17:1558.</a></li><li><a class="nounderline abstract_t">Bunchorntavakul C, Reddy KR. Pruritus in chronic cholestatic liver disease. Clin Liver Dis 2012; 16:331.</a></li><li><a class="nounderline abstract_t">Borsook D. Opioidergic tone and pain susceptibility: interactions between reward systems and opioid receptors. Pain 2017; 158:185.</a></li><li><a class="nounderline abstract_t">Nees F, Becker S, Millenet S, et al. Brain substrates of reward processing and the μ-opioid receptor: a pathway into pain? Pain 2017; 158:212.</a></li><li><a class="nounderline abstract_t">Lee JJ, Girouard SD, Carlberg VM, Mostaghimi A. Effective use of mirtazapine for refractory pruritus associated with carcinoma en cuirasse. BMJ Support Palliat Care 2016; 6:119.</a></li><li><a class="nounderline abstract_t">Vallely JJ, Hudson KE, Locke SC, et al. Pruritus in patients with solid tumors: an overlooked supportive care need. Support Care Cancer 2019; 27:3897.</a></li><li><a class="nounderline abstract_t">Vij A, Duvic M. Prevalence and severity of pruritus in cutaneous T cell lymphoma. Int J Dermatol 2012; 51:930.</a></li><li><a class="nounderline abstract_t">Weisshaar E, Weiss M, Mettang T, et al. Paraneoplastic itch: an expert position statement from the Special Interest Group (SIG) of the International Forum on the Study of Itch (IFSI). Acta Derm Venereol 2015; 95:261.</a></li><li><a class="nounderline abstract_t">Demierre MF, Gan S, Jones J, Miller DR. Significant impact of cutaneous T-cell lymphoma on patients' quality of life: results of a 2005 National Cutaneous Lymphoma Foundation Survey. Cancer 2006; 107:2504.</a></li><li><a class="nounderline abstract_t">Saini KS, Patnaik MM, Tefferi A. Polycythemia vera-associated pruritus and its management. Eur J Clin Invest 2010; 40:828.</a></li><li><a class="nounderline abstract_t">Twycross R, Greaves MW, Handwerker H, et al. Itch: scratching more than the surface. QJM 2003; 96:7.</a></li><li><a class="nounderline abstract_t">Lober CW. Pruritus and malignancy. Clin Dermatol 1993; 11:125.</a></li><li class="breakAll">Misery L. Pruritus in cutaneous T-cell lymphomas. In: Itch, Castens E, Akiyama T (Eds), CRC Press, Boca Raton, FL 2014.</li><li><a class="nounderline abstract_t">Singer EM, Shin DB, Nattkemper LA, et al. IL-31 is produced by the malignant T-cell population in cutaneous T-Cell lymphoma and correlates with CTCL pruritus. J Invest Dermatol 2013; 133:2783.</a></li><li><a class="nounderline abstract_t">Abdel-Naser MB, Gollnick H, Orfanos CE. Aquagenic pruritus as a presenting symptom of polycythemia vera. Dermatology 1993; 187:130.</a></li><li><a class="nounderline abstract_t">Seishima M, Shimizu H, Oyama Z. Skin metastasis of breast cancer clinically undistinguished from amyopathic dermatomyositis. Eur J Dermatol 2001; 11:131.</a></li><li class="breakAll">Twycross R. Pruritus and pain in en cuirass breast cancer. In: Pain Relief in Advanced Cancer, Twycross R (Ed), Churchill Livingstone, Edinburgh 1994. p.209.</li><li><a class="nounderline abstract_t">Milazzo F, Piconi S, Trabattoni D, et al. Intractable pruritus in HIV infection: immunologic characterization. Allergy 1999; 54:266.</a></li><li><a class="nounderline abstract_t">Kumar K, Singh SI. Neuraxial opioid-induced pruritus: An update. J Anaesthesiol Clin Pharmacol 2013; 29:303.</a></li><li><a class="nounderline abstract_t">Shah MK, Sia AT, Chong JL. The effect of the addition of ropivacaine or bupivacaine upon pruritus induced by intrathecal fentanyl in labour. Anaesthesia 2000; 55:1008.</a></li><li><a class="nounderline abstract_t">Kyriakides K, Hussain SK, Hobbs GJ. Management of opioid-induced pruritus: a role for 5-HT3 antagonists? Br J Anaesth 1999; 82:439.</a></li><li><a class="nounderline abstract_t">Yeh HM, Chen LK, Lin CJ, et al. Prophylactic intravenous ondansetron reduces the incidence of intrathecal morphine-induced pruritus in patients undergoing cesarean delivery. Anesth Analg 2000; 91:172.</a></li><li><a class="nounderline abstract_t">Dahlgren G, Hultstrand C, Jakobsson J, et al. Intrathecal sufentanil, fentanyl, or placebo added to bupivacaine for cesarean section. Anesth Analg 1997; 85:1288.</a></li><li><a class="nounderline abstract_t">Scott PV, Fischer HB. Spinal opiate analgesia and facial pruritus: a neural theory. Postgrad Med J 1982; 58:531.</a></li><li><a class="nounderline abstract_t">Stocks GM, Hallworth SP, Fernando R, et al. Minimum local analgesic dose of intrathecal bupivacaine in labor and the effect of intrathecal fentanyl. Anesthesiology 2001; 94:593.</a></li><li><a class="nounderline abstract_t">Milner AR, Bogod DG, Harwood RJ. Intrathecal administration of morphine for elective Caesarean section. A comparison between 0.1 mg and 0.2 mg. Anaesthesia 1996; 51:871.</a></li><li><a class="nounderline abstract_t">Swart M, Sewell J, Thomas D. Intrathecal morphine for caesarean section: an assessment of pain relief, satisfaction and side-effects. Anaesthesia 1997; 52:373.</a></li><li><a class="nounderline abstract_t">Smith TJ, Staats PS, Deer T, et al. Randomized clinical trial of an implantable drug delivery system compared with comprehensive medical management for refractory cancer pain: impact on pain, drug-related toxicity, and survival. J Clin Oncol 2002; 20:4040.</a></li><li><a class="nounderline abstract_t">Krajnik M, Zylicz Z. Understanding pruritus in systemic disease. J Pain Symptom Manage 2001; 21:151.</a></li><li><a class="nounderline abstract_t">Werawatganon T, Charuluxanun S. Patient controlled intravenous opioid analgesia versus continuous epidural analgesia for pain after intra-abdominal surgery. Cochrane Database Syst Rev 2005; :CD004088.</a></li><li><a class="nounderline abstract_t">DiGiusto M, Bhalla T, Martin D, et al. Patient-controlled analgesia in the pediatric population: morphine versus hydromorphone. J Pain Res 2014; 7:471.</a></li><li><a class="nounderline abstract_t">Hong D, Flood P, Diaz G. The side effects of morphine and hydromorphone patient-controlled analgesia. Anesth Analg 2008; 107:1384.</a></li><li><a class="nounderline abstract_t">Hutchinson R, Chon EH, Tucker W Jr, et al. A comparison of a fentanyl, morphine, and hydromorphone patient-controlled intravenous delivery for acute postoperative analgesia: a multicenter study of opioid-induced adverse reactions. Hosp Pharm 2006; 41:659.</a></li><li><a class="nounderline abstract_t">Rapp SE, Egan KJ, Ross BK, et al. A multidimensional comparison of morphine and hydromorphone patient-controlled analgesia. Anesth Analg 1996; 82:1043.</a></li><li><a class="nounderline abstract_t">Ganesh A, Maxwell LG. Pathophysiology and management of opioid-induced pruritus. Drugs 2007; 67:2323.</a></li><li><a class="nounderline abstract_t">Thomas DA, Williams GM, Iwata K, et al. The medullary dorsal horn. A site of action of morphine in producing facial scratching in monkeys. Anesthesiology 1993; 79:548.</a></li><li><a class="nounderline abstract_t">Ko MC, Song MS, Edwards T, et al. The role of central mu opioid receptors in opioid-induced itch in primates. J Pharmacol Exp Ther 2004; 310:169.</a></li><li><a class="nounderline abstract_t">Charuluxananan S, Kyokong O, Somboonviboon W, et al. Nalbuphine versus ondansetron for prevention of intrathecal morphine-induced pruritus after cesarean delivery. Anesth Analg 2003; 96:1789.</a></li><li><a class="nounderline abstract_t">Gunter JB, McAuliffe J, Gregg T, et al. Continuous epidural butorphanol relieves pruritus associated with epidural morphine infusions in children. Paediatr Anaesth 2000; 10:167.</a></li><li><a class="nounderline abstract_t">Jeon Y, Hwang J, Kang J, et al. Effects of epidural naloxone on pruritus induced by epidural morphine: a randomized controlled trial. Int J Obstet Anesth 2005; 14:22.</a></li><li><a class="nounderline abstract_t">Maxwell LG, Kaufmann SC, Bitzer S, et al. The effects of a small-dose naloxone infusion on opioid-induced side effects and analgesia in children and adolescents treated with intravenous patient-controlled analgesia: a double-blind, prospective, randomized, controlled study. Anesth Analg 2005; 100:953.</a></li><li><a class="nounderline abstract_t">Okutomi T, Saito M, Mochizuki J, Amano K. Prophylactic epidural naloxone reduces the incidence and severity of neuraxial fentanyl-induced pruritus during labour analgesia in primiparous parturients. Can J Anaesth 2003; 50:961.</a></li><li><a class="nounderline abstract_t">Rosow CE, Moss J, Philbin DM, Savarese JJ. Histamine release during morphine and fentanyl anesthesia. Anesthesiology 1982; 56:93.</a></li><li><a class="nounderline abstract_t">Flacke JW, Flacke WE, Bloor BC, et al. Histamine release by four narcotics: a double-blind study in humans. Anesth Analg 1987; 66:723.</a></li><li class="breakAll">https://academic.oup.com/brain/article/144/2/665/6053686 (Accessed on March 08, 2021).</li><li><a class="nounderline abstract_t">Borgeat A, Stirnemann HR. Ondansetron is effective to treat spinal or epidural morphine-induced pruritus. Anesthesiology 1999; 90:432.</a></li><li><a class="nounderline abstract_t">Charuluxananan S, Somboonviboon W, Kyokong O, Nimcharoendee K. Ondansetron for treatment of intrathecal morphine-induced pruritus after cesarean delivery. Reg Anesth Pain Med 2000; 25:535.</a></li><li><a class="nounderline abstract_t">Iatrou CA, Dragoumanis CK, Vogiatzaki TD, et al. Prophylactic intravenous ondansetron and dolasetron in intrathecal morphine-induced pruritus: a randomized, double-blinded, placebo-controlled study. Anesth Analg 2005; 101:1516.</a></li><li><a class="nounderline abstract_t">George RB, Allen TK, Habib AS. Serotonin receptor antagonists for the prevention and treatment of pruritus, nausea, and vomiting in women undergoing cesarean delivery with intrathecal morphine: a systematic review and meta-analysis. Anesth Analg 2009; 109:174.</a></li><li><a class="nounderline abstract_t">Levy JH, Brister NW, Shearin A, et al. Wheal and flare responses to opioids in humans. Anesthesiology 1989; 70:756.</a></li><li><a class="nounderline abstract_t">Barth H, Giertz H, Schmal A, Lorenz W. Anaphylactoid reactions and histamine release do not occur after application of the opioid tramadol. Agents Actions 1987; 20:310.</a></li><li><a class="nounderline abstract_t">Hermens JM, Ebertz JM, Hanifin JM, Hirshman CA. Comparison of histamine release in human skin mast cells induced by morphine, fentanyl, and oxymorphone. Anesthesiology 1985; 62:124.</a></li><li><a class="nounderline abstract_t">McNicol E, Horowicz-Mehler N, Fisk RA, et al. Management of opioid side effects in cancer-related and chronic noncancer pain: a systematic review. J Pain 2003; 4:231.</a></li><li><a class="nounderline abstract_t">Warner MA, Hosking MP, Gray JR, et al. Narcotic-induced histamine release: a comparison of morphine, oxymorphone, and fentanyl infusions. J Cardiothorac Vasc Anesth 1991; 5:481.</a></li><li><a class="nounderline abstract_t">Young TA, Patel TS, Camacho F, et al. A pramoxine-based anti-itch lotion is more effective than a control lotion for the treatment of uremic pruritus in adult hemodialysis patients. J Dermatolog Treat 2009; 20:76.</a></li><li><a class="nounderline abstract_t">Reilly JF Jr, Weisse ME. Topically induced diphenhydramine toxicity. J Emerg Med 1990; 8:59.</a></li><li><a class="nounderline abstract_t">Papoiu AD, Yosipovitch G. Topical capsaicin. The fire of a 'hot' medicine is reignited. Expert Opin Pharmacother 2010; 11:1359.</a></li><li><a class="nounderline abstract_t">Gooding SM, Canter PH, Coelho HF, et al. Systematic review of topical capsaicin in the treatment of pruritus. Int J Dermatol 2010; 49:858.</a></li><li class="breakAll">https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD008320.pub4/full (Accessed on May 08, 2023).</li><li><a class="nounderline abstract_t">Zylicz Z, Krajnik M, Sorge AA, Costantini M. Paroxetine in the treatment of severe non-dermatological pruritus: a randomized, controlled trial. J Pain Symptom Manage 2003; 26:1105.</a></li><li><a class="nounderline abstract_t">Ständer S, Böckenholt B, Schürmeyer-Horst F, et al. Treatment of chronic pruritus with the selective serotonin re-uptake inhibitors paroxetine and fluvoxamine: results of an open-labelled, two-arm proof-of-concept study. Acta Derm Venereol 2009; 89:45.</a></li><li><a class="nounderline abstract_t">Davis MP, Frandsen JL, Walsh D, et al. Mirtazapine for pruritus. J Pain Symptom Manage 2003; 25:288.</a></li><li><a class="nounderline abstract_t">Hundley JL, Yosipovitch G. Mirtazapine for reducing nocturnal itch in patients with chronic pruritus: a pilot study. J Am Acad Dermatol 2004; 50:889.</a></li><li><a class="nounderline abstract_t">Demierre MF, Taverna J. Mirtazapine and gabapentin for reducing pruritus in cutaneous T-cell lymphoma. J Am Acad Dermatol 2006; 55:543.</a></li><li><a class="nounderline abstract_t">Rowe B, Yosipovitch G. Paraneoplastic Itch Management. Curr Probl Dermatol 2016; 50:149.</a></li><li><a class="nounderline abstract_t">Serrano L, Martinez-Escala ME, Zhou XA, Guitart J. Pruritus in Cutaneous T-Cell Lymphoma and Its Management. Dermatol Clin 2018; 36:245.</a></li><li><a class="nounderline abstract_t">Ahuja RB, Gupta GK. A four arm, double blind, randomized and placebo controlled study of pregabalin in the management of post-burn pruritus. Burns 2013; 39:24.</a></li><li><a class="nounderline abstract_t">Brightman L, Demierre MF. Thalidomide in mycosis fungoides. J Am Acad Dermatol 2005; 52:1100.</a></li><li><a class="nounderline abstract_t">Gonçalves F. Thalidomide for the control of severe paraneoplastic pruritus associated with Hodgkin's disease. Am J Hosp Palliat Care 2010; 27:486.</a></li><li><a class="nounderline abstract_t">Haslett PA, Corral LG, Albert M, Kaplan G. Thalidomide costimulates primary human T lymphocytes, preferentially inducing proliferation, cytokine production, and cytotoxic responses in the CD8+ subset. J Exp Med 1998; 187:1885.</a></li><li><a class="nounderline abstract_t">Metze D, Reimann S, Beissert S, Luger T. Efficacy and safety of naltrexone, an oral opiate receptor antagonist, in the treatment of pruritus in internal and dermatological diseases. J Am Acad Dermatol 1999; 41:533.</a></li><li><a class="nounderline abstract_t">Ingber S, Cohen PD. Successful treatment of refractory aquagenic pruritus with naltrexone. J Cutan Med Surg 2005; 9:215.</a></li><li><a class="nounderline abstract_t">Phan NQ, Bernhard JD, Luger TA, Ständer S. Antipruritic treatment with systemic μ-opioid receptor antagonists: a review. J Am Acad Dermatol 2010; 63:680.</a></li><li><a class="nounderline abstract_t">Dawn AG, Yosipovitch G. Butorphanol for treatment of intractable pruritus. J Am Acad Dermatol 2006; 54:527.</a></li><li><a class="nounderline abstract_t">Phan NQ, Lotts T, Antal A, et al. Systemic kappa opioid receptor agonists in the treatment of chronic pruritus: a literature review. Acta Derm Venereol 2012; 92:555.</a></li><li><a class="nounderline abstract_t">Booken N, Heck M, Nicolay JP, et al. Oral aprepitant in the therapy of refractory pruritus in erythrodermic cutaneous T-cell lymphoma. Br J Dermatol 2011; 164:665.</a></li><li><a class="nounderline abstract_t">Duval A, Dubertret L. Aprepitant as an antipruritic agent? N Engl J Med 2009; 361:1415.</a></li><li><a class="nounderline abstract_t">He F, Jiang Y, Li L. The effect of naloxone treatment on opioid-induced side effects: A meta-analysis of randomized and controlled trails. Medicine (Baltimore) 2016; 95:e4729.</a></li><li><a class="nounderline abstract_t">Abboud TK, Afrasiabi A, Davidson J, et al. Prophylactic oral naltrexone with epidural morphine: effect on adverse reactions and ventilatory responses to carbon dioxide. Anesthesiology 1990; 72:233.</a></li><li><a class="nounderline abstract_t">Abboud TK, Lee K, Zhu J, et al. Prophylactic oral naltrexone with intrathecal morphine for cesarean section: effects on adverse reactions and analgesia. Anesth Analg 1990; 71:367.</a></li><li><a class="nounderline abstract_t">Jannuzzi RG. Nalbuphine for Treatment of Opioid-induced Pruritus: A Systematic Review of Literature. Clin J Pain 2016; 32:87.</a></li><li><a class="nounderline abstract_t">Anand S. Gabapentin for pruritus in palliative care. Am J Hosp Palliat Care 2013; 30:192.</a></li><li><a class="nounderline abstract_t">Ko MJ, Yang JY, Wu HY, et al. Narrowband ultraviolet B phototherapy for patients with refractory uraemic pruritus: a randomized controlled trial. Br J Dermatol 2011; 165:633.</a></li></ol></div><div id="topicVersionRevision">Topic 86291 Version 24.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23197905" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Effect of the pruritus on the quality of life: a preliminary study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18550210" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : A pilot quality-of-life instrument for pruritus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28513987" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Dermatological diseases in palliative care patients: a prospective study of 271 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17598029" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Clinical classification of itch: a position paper of the International Forum for the Study of Itch.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24217858" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Uraemic pruritus markedly affects the quality of life and depressive symptoms in haemodialysis patients with end-stage renal disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16968725" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Pruritus in haemodialysis patients: International results from the Dialysis Outcomes and Practice Patterns Study (DOPPS).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12198205" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Uraemic pruritus--new perspectives and insights from recent trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22541702" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Pruritus in chronic cholestatic liver disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28092322" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Opioidergic tone and pain susceptibility: interactions between reward systems and opioid receptors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28092323" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Brain substrates of reward processing and theμ-opioid receptor: a pathway into pain?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25515938" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Effective use of mirtazapine for refractory pruritus associated with carcinoma en cuirasse.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30762144" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Pruritus in patients with solid tumors: an overlooked supportive care need.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22788808" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Prevalence and severity of pruritus in cutaneous T cell lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25179683" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Paraneoplastic itch: an expert position statement from the Special Interest Group (SIG) of the International Forum on the Study of Itch (IFSI).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17048251" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Significant impact of cutaneous T-cell lymphoma on patients' quality of life: results of a 2005 National Cutaneous Lymphoma Foundation Survey.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20597963" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Polycythemia vera-associated pruritus and its management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12509645" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Itch: scratching more than the surface.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8339186" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Pruritus and malignancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8339186" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Pruritus and malignancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23698099" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : IL-31 is produced by the malignant T-cell population in cutaneous T-Cell lymphoma and correlates with CTCL pruritus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8358102" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Aquagenic pruritus as a presenting symptom of polycythemia vera.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11275811" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Skin metastasis of breast cancer clinically undistinguished from amyopathic dermatomyositis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11275811" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Skin metastasis of breast cancer clinically undistinguished from amyopathic dermatomyositis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10321563" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Intractable pruritus in HIV infection: immunologic characterization.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24106351" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Neuraxial opioid-induced pruritus: An update.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11012498" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : The effect of the addition of ropivacaine or bupivacaine upon pruritus induced by intrathecal fentanyl in labour.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10434832" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Management of opioid-induced pruritus: a role for 5-HT3 antagonists?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10866907" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Prophylactic intravenous ondansetron reduces the incidence of intrathecal morphine-induced pruritus in patients undergoing cesarean delivery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9390596" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Intrathecal sufentanil, fentanyl, or placebo added to bupivacaine for cesarean section.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6755416" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Spinal opiate analgesia and facial pruritus: a neural theory.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11379678" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Minimum local analgesic dose of intrathecal bupivacaine in labor and the effect of intrathecal fentanyl.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8882255" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Intrathecal administration of morphine for elective Caesarean section. A comparison between 0.1 mg and 0.2 mg.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9135193" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Intrathecal morphine for caesarean section: an assessment of pain relief, satisfaction and side-effects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12351602" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Randomized clinical trial of an implantable drug delivery system compared with comprehensive medical management for refractory cancer pain: impact on pain, drug-related toxicity, and survival.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11226766" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Understanding pruritus in systemic disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15674928" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Patient controlled intravenous opioid analgesia versus continuous epidural analgesia for pain after intra-abdominal surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25152630" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Patient-controlled analgesia in the pediatric population: morphine versus hydromorphone.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18806056" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : The side effects of morphine and hydromorphone patient-controlled analgesia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : A comparison of a fentanyl, morphine, and hydromorphone patient-controlled intravenous delivery for acute postoperative analgesia: a multicenter study of opioid-induced adverse reactions</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8610865" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : A multidimensional comparison of morphine and hydromorphone patient-controlled analgesia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17983254" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Pathophysiology and management of opioid-induced pruritus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8363081" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : The medullary dorsal horn. A site of action of morphine in producing facial scratching in monkeys.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15044556" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : The role of central mu opioid receptors in opioid-induced itch in primates.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12761013" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Nalbuphine versus ondansetron for prevention of intrathecal morphine-induced pruritus after cesarean delivery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10736080" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Continuous epidural butorphanol relieves pruritus associated with epidural morphine infusions in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15627534" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Effects of epidural naloxone on pruritus induced by epidural morphine: a randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15781505" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : The effects of a small-dose naloxone infusion on opioid-induced side effects and analgesia in children and adolescents treated with intravenous patient-controlled analgesia: a double-blind, prospective, randomized, controlled study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14617598" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Prophylactic epidural naloxone reduces the incidence and severity of neuraxial fentanyl-induced pruritus during labour analgesia in primiparous parturients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6172999" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Histamine release during morphine and fentanyl anesthesia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2440351" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Histamine release by four narcotics: a double-blind study in humans.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2440351" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Histamine release by four narcotics: a double-blind study in humans.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9952149" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Ondansetron is effective to treat spinal or epidural morphine-induced pruritus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11009242" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Ondansetron for treatment of intrathecal morphine-induced pruritus after cesarean delivery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16244023" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Prophylactic intravenous ondansetron and dolasetron in intrathecal morphine-induced pruritus: a randomized, double-blinded, placebo-controlled study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19535708" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Serotonin receptor antagonists for the prevention and treatment of pruritus, nausea, and vomiting in women undergoing cesarean delivery with intrathecal morphine: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2470272" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Wheal and flare responses to opioids in humans.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2440284" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Anaphylactoid reactions and histamine release do not occur after application of the opioid tramadol.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2578752" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Comparison of histamine release in human skin mast cells induced by morphine, fentanyl, and oxymorphone.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14622694" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Management of opioid side effects in cancer-related and chronic noncancer pain: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1718477" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Narcotic-induced histamine release: a comparison of morphine, oxymorphone, and fentanyl infusions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18821119" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : A pramoxine-based anti-itch lotion is more effective than a control lotion for the treatment of uremic pruritus in adult hemodialysis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2351800" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Topically induced diphenhydramine toxicity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20446852" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Topical capsaicin. The fire of a 'hot' medicine is reignited.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21128913" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Systematic review of topical capsaicin in the treatment of pruritus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21128913" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Systematic review of topical capsaicin in the treatment of pruritus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14654262" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Paroxetine in the treatment of severe non-dermatological pruritus: a randomized, controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19197541" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Treatment of chronic pruritus with the selective serotonin re-uptake inhibitors paroxetine and fluvoxamine: results of an open-labelled, two-arm proof-of-concept study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12614964" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Mirtazapine for pruritus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15153889" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Mirtazapine for reducing nocturnal itch in patients with chronic pruritus: a pilot study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16908377" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Mirtazapine and gabapentin for reducing pruritus in cutaneous T-cell lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27578084" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Paraneoplastic Itch Management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29929596" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Pruritus in Cutaneous T-Cell Lymphoma and Its Management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23089176" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : A four arm, double blind, randomized and placebo controlled study of pregabalin in the management of post-burn pruritus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15928639" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Thalidomide in mycosis fungoides.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20231735" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Thalidomide for the control of severe paraneoplastic pruritus associated with Hodgkin's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9607928" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Thalidomide costimulates primary human T lymphocytes, preferentially inducing proliferation, cytokine production, and cytotoxic responses in the CD8+ subset.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10495371" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Efficacy and safety of naltrexone, an oral opiate receptor antagonist, in the treatment of pruritus in internal and dermatological diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16502200" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Successful treatment of refractory aquagenic pruritus with naltrexone.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20462660" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Antipruritic treatment with systemicμ-opioid receptor antagonists: a review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16488311" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Butorphanol for treatment of intractable pruritus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22504709" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Systemic kappa opioid receptor agonists in the treatment of chronic pruritus: a literature review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21039410" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Oral aprepitant in the therapy of refractory pruritus in erythrodermic cutaneous T-cell lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19797294" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Aprepitant as an antipruritic agent?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27631221" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : The effect of naloxone treatment on opioid-induced side effects: A meta-analysis of randomized and controlled trails.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2105673" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Prophylactic oral naltrexone with epidural morphine: effect on adverse reactions and ventilatory responses to carbon dioxide.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2205128" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Prophylactic oral naltrexone with intrathecal morphine for cesarean section: effects on adverse reactions and analgesia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26650717" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Nalbuphine for Treatment of Opioid-induced Pruritus: A Systematic Review of Literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22556282" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Gabapentin for pruritus in palliative care.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21668425" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Narrowband ultraviolet B phototherapy for patients with refractory uraemic pruritus: a randomized controlled trial.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
